Oral direct-acting antiviral therapy to prevent reinfection of the liver graft after liver transplantation for hepatitis C virus–related cirrhosis

Authors


Address reprint requests to Paul Y. Kwo, M.D., Department of Medicine, Indiana University School of Medicine, 975 West Walnut, IB 327, Indianapolis, IN 46202-5121. Telephone: 317-274-3090; FAX: 317-274-3106; E-mail: pkwo@iu.edu

No abstract is available for this article.

Ancillary